NAMSW

NewAmsterdam Pharma Comp... (NAMSW)

NewAmsterdam Pharma Company NV

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:NAMSW

1 2 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/11	21:12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/06/11	21:00	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/06/08	05:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/06/08	05:01	GlobeNewswire Inc.	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/05/29	21:00	GlobeNewswire Inc.	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/05/21	21:00	GlobeNewswire Inc.	NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/05/10	05:18	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/05/10	05:15	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/05/09	21:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/05/09	21:00	GlobeNewswire Inc.	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/05/09	05:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/05/04	05:01	GlobeNewswire Inc.	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/05/02	21:00	GlobeNewswire Inc.	NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/04/09	21:00	GlobeNewswire Inc.	NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/04/01	21:00	GlobeNewswire Inc.	NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/03/25	21:00	GlobeNewswire Inc.	NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/03/12	21:00	GlobeNewswire Inc.	NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/02/28	22:00	GlobeNewswire Inc.	NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/02/26	22:00	GlobeNewswire Inc.	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/02/14	12:40	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/02/14	06:01	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/02/02	06:01	GlobeNewswire Inc.	NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/01/08	22:00	GlobeNewswire Inc.	NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2024/01/04	22:00	GlobeNewswire Inc.	NewAmsterdam Pharma Announces 2024 Strategic Priorities	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2023/11/13	22:00	GlobeNewswire Inc.	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2023/10/23	21:00	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2023/09/21	20:00	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2023/09/20	21:00	GlobeNewswire Inc.	NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2023/08/15	05:01	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV
2023/08/07	20:15	GlobeNewswire Inc.	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights	NASDAQ:NAMSW	NewAmsterdam Pharma Company NV